Search clinical trials for: Gemcitabine

Total 3056 results

HonorHealth Research Institute
Cancer Research UK; University of Arizona; Stand Up To Cancer; Lustgarten Foundation and other collaborators

Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Pancreatic Adenocarcinoma Resectable | Pancreas Metastases

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
Chimerix
Translational Drug Development

Terminated

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients (PGPC1)

Metastatic Pancreatic Cancer

United States
Incyte Corporation

Terminated

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Solid Tumors

United States, Belgium, France
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

Prostate Adenocarcinoma

United States
University of Turin, Italy

Unknown

The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial (EPIC)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Stage IV, NSCLC

Italy
PD Dr. med. Volker Heinemann
University of Cologne; Technical University of Munich

Unknown

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer (AFFECT)

Metastatic Pancreatic Cancer

Germany
Stanford University
Johns Hopkins University

Completed

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Peng Yuan

Unknown

Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Eli Lilly and Company

Completed

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

Breast Cancer

Italy, Spain, Turkey, Germany, South Africa
University of Michigan Rogel Cancer Center
Eli Lilly and Company; Barbara Ann Karmanos Cancer Institute

Completed

Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Unresectable Extrahepatic Bile Duct Carcinoma | Recurrent Cholangiocarcinoma | Non-Resectable Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IIIA Hilar Cholangiocarcinoma | Stage IIIB Hilar Cholangiocarcinoma | Stage IVA Hilar Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma and other conditions

United States
M.D. Anderson Cancer Center

Withdrawn

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Lymphoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditions | Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

China
University Medical Center Groningen
Netherlands Heart Foundation; Dutch Kidney Foundation

Completed

Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND-IT)

Cardiovascular Diseases | Microalbuminuria | Renal Disease
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States, Israel, Canada
HonorHealth Research Institute

Completed

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

Traumatic Brain Injury

United States
Fox Chase Cancer Center

Recruiting

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Small-cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
Sabine Mueller, MD, PhD
National Cancer Institute (NCI); Dana-Farber Cancer Institute; Mithil Prasad... and other collaborators

Recruiting

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (PNOC023)

Glioblastoma | Recurrent Ependymoma | CNS Tumor | Diffuse Midline Glioma (DMG) | Recurrent Malignant Central Nervous System Neoplasm | Spinal Cord Glioma | Central Nervous System Tumor | World Health Organization (WHO) Grade III Glioma

United States, Switzerland
Noah Hahn, M.D.
AstraZeneca; Hoosier Cancer Research Network

Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (ADAPT-BLADDER)

Bladder Cancer | Urothelial Carcinoma

United States
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
National Cancer Institute, Naples

Active, not recruiting

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval (MITO-8)

Ovarian Cancer

Italy, Belgium, Germany
Medical College of Wisconsin
Cancer Research UK; Stand Up To Cancer; Lustgarten Foundation; HonorHealth Research... and other collaborators

Withdrawn

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma Resectable | Pancreatic Metastasis

United States
Centre Oscar Lambret
National Cancer Institute, France

Terminated

Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. (E-DIS)

Squamous Cell Carcinoma of Esophagus

France
Oncolytics Biotech

Completed

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

Greece
Huihan Wang

Recruiting

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

Acute Myeloid Leukemia

China
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Pfizer

Terminated

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Neuroblastoma

United States
Canadian Cancer Trials Group
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Canada
Colette Shen
AstraZeneca; University of North Carolina, Chapel Hill

Recruiting

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA)

Breast Cancer | Brain Metastases, Adult

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

Non Small Cell Lung Cancer

United States, China, Hungary, Brazil, Argentina, Canada, France, Greece, Italy, Japan, Korea, Republic of, Romania, Spain, Taiwan, Turkey
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
Nasser Hanna, M.D.
Bristol-Myers Squibb; Hoosier Cancer Research Network

Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

United States
University Health Network, Toronto
Hoffmann-La Roche; Ozmosis Research Inc.

Completed

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin's

Canada
Hitendra Patel
Cancer Research UK; Stand Up To Cancer; Lustgarten Foundation; HonorHealth Research... and other collaborators

Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma Resectable | Pancreatic Metastasis

United States
ERYtech Pharma

Completed

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

Pancreatic Adenocarcinoma Metastatic

France
Pancreatic Cancer Research Team

Completed

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer

United States
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Ovarian Neoplasms

Belgium, France, Slovakia, Spain, Sweden
Sichuan University

Recruiting

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B-Cell Lymphoma | DLBCL

Poland, United States, France, Israel, Italy, Turkey, Canada, Korea, Republic of, United Kingdom, Thailand, China

Search clinical trials for: Gemcitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations